Descripción de la empresa
HCA Healthcare, Inc. operates as a major provider of healthcare services throughout the United States, owning, managing, and operating a comprehensive network that includes hospitals, ambulatory surgery centers, freestanding emergency care facilities, urgent care locations, walk-in clinics, and diagnostic and imaging centers. The entity functions within the broader Healthcare sector and specifically within the Medical Care Facilities industry, positioning it as a critical infrastructure player in the national delivery of medical treatments. In terms of scale, the company commands a market capitalization of $105.52B and generated annual revenue of $75.60B while employing a workforce of 230,000 individuals. These valuation and revenue figures indicate that HCA holds a massive position in the healthcare landscape, reflecting its dominance in hospital services and its significant influence on the economic output of the medical care industry.
Salud financiera
The company reported a revenue of $75.60B for the trailing twelve months, with a net income of $6.78B and an EBITDA of $15.49B. The substantial gap between the $75.60B in revenue and the $6.78B in net income reveals a cost structure where operating expenses, including cost of goods sold, salaries, and overhead, consume approximately 91% of total sales before arriving at the bottom line. Free cash flow stands at $5.82B, a metric that signifies the company's robust financial flexibility to fund capital expenditures, manage debt obligations, or pursue strategic acquisitions without relying heavily on external financing. The gross margin is 41.5%, indicating the efficiency of the company in producing its medical services relative to the cost of direct inputs. Operating margin sits at 16.3%, which reflects the company's ability to control overhead and administrative costs effectively, while the profit margin of 9.0% demonstrates the final portion of revenue that translates into actual earnings for shareholders. The balance sheet shows a cash position of $1.14B against total debt of $48.70B, illustrating a highly leveraged capital structure where debt obligations significantly exceed liquid cash reserves. Although the debt-to-equity ratio is listed as N/A, the disparity between cash and debt suggests a reliance on debt financing rather than equity cushioning. The current ratio is 0.96, which indicates that the company's current assets are slightly less than its current liabilities, suggesting tight short-term liquidity that requires careful management of working capital. Return on assets is 12.4%, a figure that reveals how efficiently management utilizes the company's asset base to generate earnings. Return on equity is N/A, meaning this specific return metric is not provided in the available data to assess management effectiveness relative to shareholder equity.
Evaluación de valoración
The trailing twelve-month P/E ratio is 16.67, while the forward P/E ratio is 14.18. The difference between these two metrics implies that the market expects earnings to grow significantly in the future, as investors are pricing in lower valuation multiples relative to expected future profits. The price-to-book ratio is -17.58, a figure that indicates the market values the company at a negative multiple relative to its book value, which can occur in asset-heavy industries where assets are not fully depreciated or where intangible liabilities exist. The price-to-sales ratio is 1.40, and the EV/EBITDA multiple is 10.09; these alternative valuation metrics suggest that the company trades at a moderate premium to its sales and generates earnings relative to its enterprise value that is typical for established healthcare operators. The stock's 52-week high is $556.52 and the 52-week low is $314.43. Without the current share price explicitly listed in the provided facts, the specific percentage distance from the high cannot be calculated, but the range demonstrates a wide trading band of $242.09 over the past year. The beta value is 1.34, which means the stock price exhibits higher volatility relative to the broader market, rising and falling more sharply than the general market index during periods of equity market fluctuation.
Growth & Income
Revenue growth over the last year is 6.7%, while earnings growth is 44.5%. The fact that earnings are growing at a rate of 44.5% while revenue grows at 6.7% implies that the company is successfully improving its profitability through operational efficiencies, pricing power, or a shift toward higher-margin services. For dividend payers, the dividend yield is 0.7% with a payout ratio of 10.2%. This low payout ratio indicates that the company retains the vast majority of its earnings for reinvestment rather than distributing them to shareholders, suggesting a sustainable dividend policy given the strong earnings growth. Since the payout ratio is only 10.2%, the company is clearly retaining earnings to fuel its internal growth engines rather than focusing on maximizing immediate shareholder payouts. The overall growth and income profile presents a company in a high-g earnings expansion phase that offers a modest dividend yield while maintaining a highly leveraged balance sheet and significant operational leverage.